corporate_news

Immune Therapeutics

Shareholder Update Letter

LEARN MORE

omera_pharma

Immune Therapeutics Announces

Exclusive Agreement for Sale of Lodonal in Kenya

LEARN MORE

Valued at Over $31 Million

john_abeles_md

Immune Therapeutics, Inc

APPOINTS JOHN H. ABELES, M.D. AS CHAIRMAN AND CEO
OF COMPANY’S SUBSIDIARY, CYTOCOM, INC.
AND AS SENIOR ADVISER TO IMMUNE
THERAPEUTICS, INC.

LEARN MORE

NAFDAC

Immune Therapeutics Announces

NAFDAC Approval for Marketing & Distribution of Lodonal™

LEARN MORE

Immune Therapeutics Emerges as a Key Player in Immunotherapy Field

bg-lab-1

100+ years

Combined experience
in laboratory
research & immunology

LEARN MORE

Discover more about
our research and technology

bg-lab-2

Immunology

research and investigation

LEARN MORE

Investing in a better and healthier
world today to see it tomorrow

bg-lab-3-2

Experience

LEARN MORE

Treatment for known
autoimmune disorders & cancers

Our Projects

Latest News

Intersting Facts

Our Progress

Nigeria 96%
Kenya 65%
CAR-T 50%
Cytocom 50%

International Manufacturer

acromax logoProviding safe, effective and innovative pharmaceutical products that contribute to the well-being and health of the people since 1972

Additional info

  • Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis

  • Immune Effects of Low-dose Naltrexone in ME/CFS